PMID- 36210030 OWN - NLM STAT- MEDLINE DCOM- 20221220 LR - 20221229 IS - 2213-7173 (Electronic) IS - 2213-7165 (Linking) VI - 31 DP - 2022 Dec TI - A five-year review of prevalence and treatment outcomes of pre-extensively drug-resistant plus additional drug-resistant tuberculosis in the Henan Provincial Tuberculosis Clinical Medicine Research Centre. PG - 328-336 LID - S2213-7165(22)00226-0 [pii] LID - 10.1016/j.jgar.2022.09.010 [doi] AB - OBJECTIVES: This study investigated the prevalence and significant clinical outcomes of pre-extensively drug-resistant plus additional drug-resistant tuberculosis (pre-XDR-plus) in Henan Provincial Chest Hospital between 2017 and 2021. METHODS: We analysed and summarized the drug sensitivity test (DST) results of clinical Mycobacterium tuberculosis (MTB) strains in TB patients seeking care in the Tuberculosis Clinical Medical Research Centre of Henan Province between 2017 and 2021. Medical records of pre-extensively drug-resistant plus additional drug-resistant TB patients were statistically analysed, including demographic characteristics, regimens, and outcomes. RESULTS: Of the 3689 Mycobacterium tuberculosis strains, 639 (17.32%), 353 (9.56%), and 109 (2.95%), multidrug-resistant tuberculosis (MDR-TB), pre-extensively drug-resistant tuberculosis (pre-XDR), and pre-XDR-plus, respectively. The proportion of MDR decreased from 19.1% in 2017 to 17.5% in 2021 (chi(2) = 0.686, P = 0.407), the proportion of pre-XDR from 11.4% in 2017 to 9.0% in 2021 (chi(2) = 2.39, P = 0.122), and pre-XDR-plus from 4.7% in 2017 to 1.8% in 2020, with the declining trend was significant (chi(2) = 9.348, P = 0.002). The most commonly used anti-TB drugs were pyrazinamide (PZA, 37/46, 80.43%) and cycloserine (CS, 32/46, 69.57%), followed by linezolid (LZD, 25/46, 54.35%), protionamide (TH, 25/46, 54.35%), and para-aminosalicylic acid (PAS, 23/46, 50.00%). Patients receiving the LZD regimen were 5 times more likely to have a favourable outcome than those not receiving LZD (OR = 6.421, 95% CI 2.101-19.625, P = 0.001). Patients receiving a regimen containing CS were 4 times more likely to have a favourable outcome compared to those not taking CS (OR = 5.444, 95% CI 1.650-17.926, P = 0.005). CONCLUSIONS: Our data suggest that the population of pre-XDR-plus had significantly decreased over the past five years in the Henan Provincial Chest Hospital. The COVID-19 and flood disaster affect TB patients' selection of medical services. In addition, the pre-XDR-plus patients whose regimens contain LZD or CS were more likely to have favourable outcomes. CI - Copyright (c) 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved. FAU - Li, Zheng AU - Li Z AD - Department of Medical Laboratory, Henan Provincial Chest Hospital, Zhengzhou, China. Electronic address: 154493095@qq.com. FAU - Liu, Fuyong AU - Liu F AD - School of Basic Medical Sciences, Sanquan College of Xinxiang Medical University, Xinxiang, China. FAU - Chen, Huihui AU - Chen H AD - Department of Medical Laboratory, Henan Provincial Chest Hospital, Zhengzhou, China. FAU - Han, Yungang AU - Han Y AD - Department of Medical Laboratory, Henan Provincial Chest Hospital, Zhengzhou, China. FAU - You, Yonghe AU - You Y AD - School of Basic Medical Sciences, Sanquan College of Xinxiang Medical University, Xinxiang, China. FAU - Xie, Yongsheng AU - Xie Y AD - School of Basic Medical Sciences, Sanquan College of Xinxiang Medical University, Xinxiang, China. FAU - Zhao, Yue AU - Zhao Y AD - Department of Medical Laboratory, Henan Provincial Chest Hospital, Zhengzhou, China. FAU - Tan, Jiao AU - Tan J AD - Department of Medical Laboratory, Henan Provincial Chest Hospital, Zhengzhou, China. FAU - Guo, Xu AU - Guo X AD - Department of Medical Laboratory, Henan Provincial Chest Hospital, Zhengzhou, China. FAU - Cheng, Yuntao AU - Cheng Y AD - Department of Medical Laboratory, Henan Provincial Chest Hospital, Zhengzhou, China. FAU - Wang, Yali AU - Wang Y AD - Department of Medical Laboratory, Henan Provincial Chest Hospital, Zhengzhou, China. FAU - Li, Jing AU - Li J AD - Department of Medical Laboratory, Henan Provincial Chest Hospital, Zhengzhou, China. FAU - Cheng, Meijin AU - Cheng M AD - Department of Medical Laboratory, Henan Provincial Chest Hospital, Zhengzhou, China. FAU - Xia, Shuang AU - Xia S AD - Department of Medical Laboratory, Henan Provincial Chest Hospital, Zhengzhou, China. FAU - Niu, Xiaodong AU - Niu X AD - Department of Medical Laboratory, Henan Provincial Chest Hospital, Zhengzhou, China. FAU - Wei, Lukuan AU - Wei L AD - Department of Medical Laboratory, Henan Provincial Chest Hospital, Zhengzhou, China. FAU - Wang, Wei AU - Wang W AD - Department of Medical Laboratory, Henan Provincial Chest Hospital, Zhengzhou, China. Electronic address: jyk2785@163.com. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20221006 PL - Netherlands TA - J Glob Antimicrob Resist JT - Journal of global antimicrobial resistance JID - 101622459 RN - 0 (Antitubercular Agents) RN - 5B2658E0N2 (Aminosalicylic Acid) SB - IM MH - Humans MH - *Extensively Drug-Resistant Tuberculosis/drug therapy/epidemiology/microbiology MH - Antitubercular Agents/pharmacology/therapeutic use MH - Prevalence MH - Microbial Sensitivity Tests MH - *COVID-19 MH - *Tuberculosis, Multidrug-Resistant/drug therapy/epidemiology/microbiology MH - *Mycobacterium tuberculosis MH - *Aminosalicylic Acid MH - Treatment Outcome MH - *Clinical Medicine OTO - NOTNLM OT - CS OT - LZD OT - Mycobacterium tuberculosis OT - Pre-extensively drug-resistant EDAT- 2022/10/10 06:00 MHDA- 2022/12/21 06:00 CRDT- 2022/10/09 19:26 PHST- 2022/04/23 00:00 [received] PHST- 2022/08/20 00:00 [revised] PHST- 2022/09/23 00:00 [accepted] PHST- 2022/10/10 06:00 [pubmed] PHST- 2022/12/21 06:00 [medline] PHST- 2022/10/09 19:26 [entrez] AID - S2213-7165(22)00226-0 [pii] AID - 10.1016/j.jgar.2022.09.010 [doi] PST - ppublish SO - J Glob Antimicrob Resist. 2022 Dec;31:328-336. doi: 10.1016/j.jgar.2022.09.010. Epub 2022 Oct 6.